<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>ZIMLAB</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">ZIMLAB</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="zim-laboratories-limited" class="section level1">
<h1>Zim Laboratories Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZIMLAB.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZIMLAB.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZIMLAB.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZIMLAB.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZIMLAB.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZIMLAB.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZIMLAB.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZIMLAB.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ZIMLAB.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-11-27 </em></p>
<div id="zim-laboratories-limited-zimlab-analysis" class="section level9">
<p class="heading">ZIM Laboratories Limited (ZIMLAB) Analysis</p>
<p>ZIMLAB is a Nagpur-based pharmaceutical company focused on innovative drug delivery (NIP/OTF platforms), complex generics, and nutraceuticals, with a strong export orientation (83% of H1 FY26 revenue). FY26 has been challenging due to EU-GMP suspension, but management emphasizes remediation progress and H2 recovery. FY25 full-year revenue was ~₹3,790 Cr (implied), with H1 FY26 down 7.8% YoY to ₹1,605 Cr. Below is a structured analysis based on Q2/H1 FY26 earnings call, presentation, financials, and disclosures.</p>
<div id="headwinds-current-challenges" class="section level12">
<p class="heading"><strong>Headwinds (Current Challenges)</strong></p>
<ul>
<li><strong>EU-GMP Audit Non-Compliance</strong>: Primary issue from a German auditor—critical observations on manual HVAC log books (e.g., incomplete entries, pen left inside, perceived “fraud intent”). Led to suspension of supplies from the main plant to EU/UK, severely impacting NIP/OTF sales (H1 FY26: ₹127 Cr vs. ₹343 Cr YoY, down 63%). No product quality deviations found, but halted new MA filings from this site.</li>
<li><strong>Revenue &amp; Profitability Pressure</strong>: H1 FY26 revenue down 7.8% YoY; EBITDA margins compressed to 8.4% (vs. 11.4% YoY) due to product mix shift, deferred Nutra orders (domestic institutional), and lower innovative sales. Q2 PAT loss ₹4 Cr (improved from ₹19 Cr in Q1).</li>
<li><strong>Nutraceutical Segment Weakness</strong>: 17% of Q2 revenue (₹155 Cr), down QoQ due to deferred domestic orders; expected recovery in H2.</li>
<li><strong>Working Capital Strain</strong>: Inventory days up to 109 (from 83); receivables elevated; debt peaked at ₹117 Cr (gearing ~48%, stable but monitored).</li>
<li><strong>Capex &amp; R&amp;D Drag</strong>: ₹72 Cr capex in H1 (incl. ₹51 Cr BE studies); R&amp;D at 9.7% of revenue—high but supportive of pipeline.</li>
</ul>
</div>
<div id="tailwinds-positive-factors" class="section level12">
<p class="heading"><strong>Tailwinds (Positive Factors)</strong></p>
<ul>
<li><strong>Sequential Recovery</strong>: Q2 revenue up 23.6% QoQ to ₹887 Cr; Pharma (83% mix) up 30.7% QoQ; EBITDA margins improved to 8.8%.</li>
<li><strong>Strong Order Book &amp; H2 Visibility</strong>: Robust PMI/export orders; 60% historical H2 skew; deferred Nutra orders to materialize. FY26 guidance: revenues “broadly in line” with FY25.</li>
<li><strong>Business Continuity Measures</strong>:
<ul>
<li>Site transfers for key “Star Products” (e.g., Tamsulosin+Dutasteride to TGA site; Dimethyl Fumarate/Azithromycin to EU/MHRA sites)—commercial supplies in 3-6 months (Q4 FY26/Q1 FY27).</li>
<li>4 new MAs received (TGA, MHRA); NIP/OTF contribution up 78% QoQ to ₹81 Cr in Q2.</li>
</ul></li>
<li><strong>Remediation Momentum</strong>: CAPA accepted; 3 Action Taken Reports submitted; Indian/European consultants hired; shift to electronic documentation (21CFR compliant). Target re-audit: March 2026.</li>
<li><strong>Export Resilience</strong>: 82-83% mix; base business (PFI/formulations) stabilizing post-currency issues; ROW/emerging market traction.</li>
<li><strong>Balance Sheet Stability</strong>: Net worth ₹2,513 Cr; cash from ops ₹199 Cr in H1; promoter pledge nil (holding ~43%).</li>
</ul>
</div>
<div id="growth-prospects" class="section level12">
<p class="heading"><strong>Growth Prospects</strong></p>
<ul>
<li><strong>Short-Term (FY26 H2/FY27)</strong>: Flat FY26 revenues (~₹3,800 Cr); H2 EBITDA jump to ~₹30 Cr implied (to match FY25). Site transfers safeguard ~₹100-150 Cr NIP revenue; Nutra normalization.</li>
<li><strong>Medium-Term (Post-EU Clearance)</strong>: EU-GMP resumption unlocks regulated markets (EU/UK/Aus); 12+ NIP/OTF pipeline products (urology, GI, CNS) nearing commercialization. Non-infringing processes (e.g., Dimethyl Fumarate) offer margin upside. Prior guidance: 20-25% revenue growth + 14-15% EBITDA margins in FY27 (delayed 3-6 months).</li>
<li><strong>Long-Term Drivers</strong>:
<ul>
<li>Innovation focus: R&amp;D ₹155 Cr (9.7% revenue); OTF/NIP platforms differentiate in crowded generics/Nutra.</li>
<li>Diversification: Emerging markets (ROW) approvals; licensing income (₹29 Cr in Q2).</li>
<li>Capacity: Capex completed (~₹10 Cr more for CAPA); new land acquired post-quarter.</li>
</ul></li>
<li><strong>Catalysts</strong>: Pancreatin MA (shortage-driven); MHRA/TGA launches; re-audit success.</li>
</ul>
</div>
<div id="key-risks" class="section level12">
<p class="heading"><strong>Key Risks</strong></p>
<table>
<colgroup>
<col width="33%" />
<col width="28%" />
<col width="38%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk Category</strong></th>
<th><strong>Description</strong></th>
<th><strong>Mitigation/Impact</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory</strong></td>
<td>EU re-audit delay beyond March 2026; further observations.</td>
<td>Consultants/electronic shift; alternate sites; product shortages may accelerate (e.g., Pancreatin). High impact if prolonged.</td>
</tr>
<tr class="even">
<td><strong>Operational</strong></td>
<td>Site transfer delays/margin dilution (marginal, still double-digit). Inventory/receivables stretch (78-109 days).</td>
<td>Strong order book; H2 execution. Medium impact.</td>
</tr>
<tr class="odd">
<td><strong>Financial</strong></td>
<td>Debt servicing (₹646 Cr finance cost H1); forex volatility.</td>
<td>Ops cash positive; no new debt planned. Low-moderate.</td>
</tr>
<tr class="even">
<td><strong>Market</strong></td>
<td>Nutra competition/price pressure; emerging market delays.</td>
<td>Tech platforms provide edge. Low impact.</td>
</tr>
<tr class="odd">
<td><strong>Governance/Ownership</strong></td>
<td>Low promoter holding (~33-43%); recent director re-appointments via postal ballot (passed overwhelmingly).</td>
<td>Passed with 99.9% votes; no pledges. Low.</td>
</tr>
<tr class="even">
<td><strong>Execution</strong></td>
<td>CAPA culture shift; consultant effectiveness.</td>
<td>3 reports accepted; on-track per mgmt. High if fails.</td>
</tr>
</tbody>
</table>
</div>
<div id="overall-summary" class="section level12">
<p class="heading"><strong>Overall Summary</strong></p>
<p>ZIMLAB faces near-term <strong>headwinds from EU-GMP suspension</strong> (core issue dragging innovative sales/margins), but <strong>tailwinds from remediation progress, site transfers, and H2 order book</strong> position it for FY26 stability and FY27 re-rating. Growth hinges on March 2026 re-audit success—unlocking 20-25% revenue CAGR potential via pipeline/regulated markets. <strong>Valuation opportunity</strong> if execution holds (current implied multiples low post-H1 losses); monitor Q3 for H2 traction. <strong>Recommendation</strong>: Accumulate on dips for patient investors; key watch: CAPA updates, NIP sales ramp. FY26 consensus: Flat growth, 10% EBITDA margins; FY27: 20%+ upside.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
